RIPK1 and neoplasm: Infiltrating CD8+ T cells could cause a better prognosis in LIHC, with RIPK1, RIPK3, and MLKL-p significantly correlated with CD3+ and CD8+ T cells in tumor (Nicolè et al., 2022; Jiang et al., 2023).